This figure illustrates overall survival in adult subjects with acute myeloid leukemia (AML, age range 15 to 86 years, median 52 years), according to the following cytogenetic risk categories: Favorable risk (median survival 7.6 years): t(8;21); inv(16) or t(16;16); del(9q). Intermediate risk (median survival 1.3 years): normal karyotype; -Y; del(5q); loss of 7q; t(9;11); +11; del(11q); abn(12p); +13; del(20q); +21. Adverse risk (median survival 0.5 years): complex karyotype (≥3 abnormalities); inv(3) or t(3;3); t(6;9); t(6;11); -7; +8 (sole abnormality); +8 with one other abnormality other than t(8;21), t(9;11), inv(16), or t(16;16); t(11;19)(q23;p13.1).
Data from Byrd, JC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8641). Blood 2002; 100:4325.
Graphic 65190 Version 3.0
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟